Enomoto Atsushi

エノモトアツシ | Enomoto Atsushi

Affiliation and department：
Job title： Professor
Homepage URL (2)： https://www.med.nagoya-u.ac.jp/patho2/ , https://www.med.nagoya-u.ac.jp/patho2/en/

Research field (1)： Experimental pathology

Research keywords (4)： Pathology , Cell biology , 細胞生物学 , 実験病理学

Research theme for competitive and other funds (27)：

2022 - 2027 線維芽細胞の多様性理解に基づく肺線維症合併肺癌の病態の解明と治療戦略の探索
2023 - 2026 脳腫瘍における治療抵抗性がん細胞の多様性の解析とその克服戦略の勘案
2022 - 2026 Analysis of mechanism of tumor stroma formation and stromal invasion in lung cancer
2022 - 2025 線維芽細胞の形質維持不全と老化が個体の生理機能と病態に与える影響の解明
2021 - 2024 間葉系幹細胞の微小環境での炎症制御機構に着眼した次世代型免疫・炎症制御法の創成

2020 - 2023 特異的な間葉系幹細胞マーカーMeflinを介した腎線維化の機序解明と治療法の開発

2020 - 2023 心臓の硬化を制御するG蛋白質共役受容体の機能解明と心不全治療薬シーズの探索

2020 - 2023 Mechanism of predicting the effects of immune checkpoint inhibitors based on the diversity of cancer-associated fibroblasts

2020 - 2023 がんの線維化におけるMeflinの機能解析と新規治療法の開発研究

2019 - 2023 Dynamic regulation of cancer associated fibroblast via functional RNA as a novel therapeutic target for pancreas cancer

2018 - 2021 Identification of molecular mechanisms that regulate the proliferation-migration dichotomy of cancer cells

2017 - 2020 Analysis of the role of mesenchymal stem cell marker Meflin in kidney fibrosis

2017 - 2020 Analysis of the role of mesenchymal stem cell marker Meflin in glomerulonephritis

2014 - 2019 Functional analysis of Girdin family proteins in psyco-neurological disease and cancer

2015 - 2018 Mechanisms and significance of collective cancer cell migration mediated by cadherin-specific endocytosis

2014 - 2016 Identification of molecular mechanisms that regulate collective invasion of cancer cells

2013 - 2016 Investigation of pathogenesis of mesial temporal epilepsy using monogenic mouse model

2013 - 2016 Investigation of discrimination and activation of Dynamin 2 GTPase by Girdin

2014 - 2015 Girdinファミリー分子の機能と精神神経疾患・がんの病態形成における役割

2012 - 2015 Mechanisms for selective endocytosis and its involvement in the pathogenesis of cancer and psychiatric disorders

2010 - 2015 Roles of Girdin phosphorylation by Akt kinase in human diseases

2011 - 2014 Molecular mechanisms of postnatal angiogenesis and neurogenesis

2011 - 2013 細胞の集団的移動と接触阻害の分子メカニズムの解明

2009 - 2011 Molecular mechanisms for neurogenesis and psychiatric dysfunction in postnatal and adult periods

2007 - 2010 Physiological functions of the Akt substrate Girdin and its family proteins and their roles in pathogenesis

2006 - 2008 Roles of the novel Akt substrate Girdin and its family of proteins in development and tumor protression

2003 - 2005 腎臓と神経の発生及び再生に関与する遺伝子の探索及びその機能の解明

Show all

Papers (281)：

Tatsuya Yoshida, Satoya Yoshida, Kohei Inukai, Katsuhiro Kato, Yoshimitsu Yura, Tomoki Hattori, Kentaro Taki, Atsushi Enomoto, Koji Ohashi, Takahiro Okumura, et al. ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2024. 38. 22. e70192
Yuki Sonoda, Masataka Hirasaki, Yoko Usami, Tomoaki Torigoe, Tomonori Kawasaki, Nobuyuki Suzuki, Yukihiro Shiraki, Atsushi Enomoto, Hiroki Imada, Yasutaka Baba. Pulmonary metastases of a renal angiomyolipoma: A case report, with whole-exome sequencing analysis. Radiology case reports. 2024. 19. 11. 4963-4969
Satoya Yoshida, Tatsuya Yoshida, Kohei Inukai, Katsuhiro Kato, Yoshimitsu Yura, Tomoki Hattori, Atsushi Enomoto, Koji Ohashi, Takahiro Okumura, Noriyuki Ouchi, et al. Protein kinase N promotes cardiac fibrosis in heart failure by fibroblast-to-myofibroblast conversion. Nature communications. 2024. 15. 1. 7638-7638
辰野力人, 市川二郎, 菰原義弘, 榎本篤, 川崎朋範, 重橋孝洋, 波呂浩孝. 骨肉腫微小環境における腫瘍関連マクロファージ由来IL-8の働き. 日本整形外科学会雑誌. 2024. 98. 8. S1968-S1968
Toshikazu Ishihara, Katsuhiro Kato, Kotaro Matsumoto, Miyako Tanaka, Akitoshi Hara, Yukihiro Shiraki, Hidenori Morisaki, Yuya Urano, Ryota Ando, Kisuke Ito, et al. Meflin/ISLR is a marker of adipose stem and progenitor cells in mice and humans that suppresses white adipose tissue remodeling and fibrosis. Genes to cells : devoted to molecular & cellular mechanisms. 2024

ｍore...

MISC (97)：

北見和久, 吉原雅人, 山北由彦, 杉山麻衣, 小屋美博, 藤本裕基, 伊吉祥平, 宇野枢, 茂木一将, 玉内学志, et al. 難治性婦人科がんの克服を目指して腫瘍促進的腹膜環境の正常化を標的とした難治性卵巣癌に対する新規治療戦略の開発. 日本婦人科腫瘍学会学術講演会プログラム・抄録集. 2022. 64回. 103-103
榎本篤, 宮井雄基, 飯田忠, 大脇貴之. Roles of cancer-associated fibroblasts and tumor vessels in ICI resistance. 実験医学. 2022. 40. 16
大脇貴之, 宮井雄基, 飯田忠, 江崎寛季, 白木之浩, 三井伸二, 榎本篤. Meflin is a good predictive biomarker for ICI in urothelial carcinoma. 日本癌学会学術総会抄録集(Web). 2022. 81st
迫田朋佳, 江崎寛季, 江崎寛季, 安藤良太, 宮井雄基, 飯田忠, 松山誠, 白木之浩, 三井伸二, 西田佳弘, et al. An Effective Therapy that Antibody-Drug Conjugates Targeting Meflin (+) Cells for Osteosarcoma. 日本癌学会学術総会抄録集(Web). 2022. 81st
飯田忠, 水谷泰之, 石川卓哉, 大野栄三郎, 川嶋啓揮, 榎本篤, 藤城光弘. 【膵癌研究最前線】癌関連線維芽細胞をターゲットにした新たな治療法. 消化器・肝臓内科. 2021. 10. 3. 382-386

ｍore...

Patents (6)：

Predictive Biomarker in PD-1/PD-L1 Immune Checkpoint Blockade Therapy
Marker for undifferentiated mesenchymal stem cells and use thereof
BIOMARXER FOR LYMPHOCYTIC INFUNDIBULONEUROHYPOPHYSITIS, AND USE APPLICATIONS THEREOF
APPLICATION OF ACTIN-BINDING PROTEIN TO DISEASE ASSOCIATED WITH CELL MOTILITY
TESTICULAR CARNITINE TRANSPORTER AND ITS GENE

ｍore...

Professional career (1)：

博士(医学) (名古屋大学)

Committee career (3)：

2015/01 - 現在日本癌学会評議員
2014/04 - 現在日本細胞生物学会代議員
2013/06 - 現在日本病理学会学術評議員

Awards (9)：

2019 - 第一回日本医学会連合Rising Starリトリート優秀賞
2017 - 日本病理学会学術研究賞(A演説) アクチン結合タンパク質Girdinの機能解析による細胞移動の統合的理解
2016 - 日本病理学会第13回日本病理学会カンファレンス最優秀ポスター賞間葉系幹細胞の未分化性維持に関わる新規マーカー分子Meflinの同定
2013 - 日本癌学会日本癌学会奨励賞がんの進展および血管新生における細胞移動の分子機構の解明
2013 - 日本腎臓学会ベストサイテーション賞 Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease (Clin Exp Nephrol. 9:195-205, 2005)

Show all

Association Membership(s) (5)：

日本メカノバイオロジー学会 , THE MOLECULAR BIOLOGY SOCIETY OF JAPAN , JAPAN SOCIETY FOR CELL BIOLOGY , THE JAPANESE SOCIETY OF PATHOLOGY , THE JAPANESE CANCER ASSOCIATION

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page